Amgen, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 163   

Articles published

AMGN 154.35 +1.33 (0.87%)
price chart
UPDATE: Amgen Inc. stock drops 2% on drug's cardiovascular risk; no approval ...
Amgen Inc. AMGN, -2.23% shares dropped 1.9% in morning trade Monday after the company said that it has observed new cardiovascular risks for its Evenity drug, which is intended to reduce risk of fractures in patients with osteoporosis, and that it does ...
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation ...
NEW YORK, May 23, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amgen, Inc. ("Amgen" or the "Company") (NASDAQ: AMGN). Such investors are encouraged to ...
Amgen Inc. (AMGN) Is Down Sharply On Drug Concerns
( - Amgen Inc. ( AMGN ) and UCB announced Sunday that the EVENITY (romosozumab) ARCH study met both primary endpoints and the key secondary endpoint.
Heart safety clouds hopes for Amgen, UCB bone drug approval  Reuters
Amgen, Inc. (AMGN) Stock Dips on Osteoporosis Drug Disappointment
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of ...
NEW YORK, May 22, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN).
SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Amgen Inc.
LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amgen Inc. (“Amgen” or the “Company”) (Nasdaq: AMGN). If you purchased or otherwise ...
Why Amgen, Inc. (AMGN), Advanced Micro Devices, Inc. (AMD) and Forterra Inc ...
In the wake of news that U.S. allies in the Middle East will be purchasing $350 billion worth of defense and military hardware over the course of the next ten years, the bulls were willing to pick up where they left off on Friday.
Better Buy: Amgen Inc. vs. Johnson & Johnson
Investors who bought shares of Amgen (NASDAQ:AMGN) five years ago are probably a happier bunch than those who went for Johnson & Johnson (NYSE:JNJ).
Amgen Is Priced To Buy
Amgen Inc. (NASDAQ:AMGN) is a dividend paying pharmaceutical company. With its current dividend and the rate at which it should be able to grow the dividend, the current market price offers a good opportunity.
Better Buy: Gilead Sciences, Inc. vs. Amgen Inc.
For much of the past five years, Gilead Sciences (NASDAQ: GILD) was a bigger biotech than Amgen (NASDAQ: AMGN) in terms of market cap.
Better Buy: Amgen Inc. vs. Biogen
With this in mind, Amgen (NASDAQ:AMGN) and Biogen (NASDAQ:BIIB) have both proven to be particularly outstanding vehicles to gain exposure to this high-flying industry.